SCOLR Pharma's ibuprofen ER phase III trial meets endpoints

SCOLR Pharma, Inc reported favourable top-line results from its pivotal phase-III trial to evaluate the safety and efficacy of its 12 hour CDT 600 mg. extended-release (ER) ibuprofen for the over-the-counter market.

The details can be read here.